Clinical trial · Interventional
Pentoxifylline Treatment in Acute Pancreatitis (AP)
Pentoxifylline Treatment in Acute Pancreatitis: A Double-Blind Placebo - Controlled Randomized Trial
NCT02487225CI-TRIAL-00036681APcompletedPhase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study was to determine the effects (good and bad) of giving a drug called pentoxifylline to patients with acute pancreatitis.
Conditions
Conditions (9)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Pancreatitis (AP) | — | UNRESOLVED | — |
| Alcoholic Pancreatitis | — | UNRESOLVED | — |
| Cancer Acute Pancreatitis | — | UNRESOLVED | — |
| Gallstone Pancreatitis | — | UNRESOLVED | — |
| Hypertriglyceridemia Acute Pancreatitis | — | UNRESOLVED | — |
| Idiopathic (Unknown) Acute Pancreatitis | — | UNRESOLVED | — |
| Medication Induced Acute Pancreatitis | — | UNRESOLVED | — |
| Miscellaneous (i.e. Acute on Chronic Pancreatitis) | — | UNRESOLVED | — |
| Trauma Acute Pancreatitis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pentoxifylline | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Pentoxifylline
- description
- Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
- interventionNames
- Drug: Pentoxifylline
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
- interventionNames
- Drug: Placebo
Primary outcomes (4)
- measure
- Change in C-reactive Protein (C-RP) From Admission Baseline at One Week.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion criteria * Enrollment within 72 hours of diagnosis of acute pancreatitis (AP) * Ability to give informed consent or a Legal Adult Representative (LAR) able to give informed consent for subject when needed as defined buy LAR use guidelines. * Adult subjects of age ≥18 years. Exclusion Criteria: * Moderate or severe congestive heart failure * History of seizure disorders or demyelinating disease * Nursing mothers * Pregnancy * History of prior tuberculosis or risk factors for tuberculosis * Evidence of non- corticosteroid immunosuppression (such as malignancy, chronic renal failure, chemotherapy within 60 days, and HIV) * Evidence of active hemorrhage * Paralytic ileus with severe nausea and vomiting
References
Publications (0)
Data not yet available
No reference posted for this study.